Should drug and supplement companies be required to alert investors whenever any adverse-event report (AERs) over a product arises-in case an AER is predictive of a larger problem with the product that could devalue shareholder stocks?
Should drug and supplement companies be required to alert investors whenever any adverse-event report (AERs) over a product arises-in case an AER is predictive of a larger problem with the product that could devalue shareholder stocks? That’s the argument the Supreme Court is debating as it listened to testimony this week in the case of Matrixx Initiatives Inc. (the maker of Zicam zinc nasal spray) vs. James Siracusano.
Read a story about this case Nutritional Outlook editor Jennifer Kwok wrote in October.
As The New York Times reports, the Supreme Court justices are debating Matrixx’s argument that “ignorant or paranoid” consumers might overreact to product reports that may be unreliable or even false.
“All drug companies receive on an almost daily basis anecdotal hearsay reports about alleged adverse health events following the use of their products,” said Jonathan Hacker, a lawyer for Matrixx, the Times reports.
Yet, the Times said, “Matrixx did not appear to get much traction for its main argument - that a failure to disclose reports of adverse effects should give rise to securities fraud liability only if the reports were collectively statistically significant,” the paper says.
On the flip side, “…the justices appeared almost uniformly skeptical of imposing a requirement of statistical significance, particularly at the very outset of a case. Justice Elena Kagan said that the F.D.A. itself did not use that standard, and she added that she could imagine situations in which small numbers of reports of serious harm would meet the securities laws’ requirement of materiality.”
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.
U.S. Hemp Authority announces Adult Use Hemp Product Certification Program
April 15th 2024The U.S. Hemp Authority (USHA) has announced the launch of its Adult Use Hemp Product Certification Program in an effort to “reshape public policy around hemp, and to build confidence among retailers and consumers alike.”